Document is current
Any future updates will be listed below
-
Authors
Fernandez, Sandra V.
MacFarlane, Alexander W. IV
Jillab, Mowafaq
Arisi, Maria F.
Yearley, Jennifer
Annamalai, Lakshmanan
Gong, Yulan
Cai, Kathy Q.
Alpaugh, R. Katherine
Cristofanilli, Massimo
Campbell, Kerry S. http://orcid.org/0000-0003-4665-7326
-
Funding
Funding for this research was provided by:
Merck
National Cancer Institute (CA06927)
Fox Chase Cancer Center
- License Information
-
More Information
Article History
Received: 22 May 2020
Accepted: 15 November 2020
First Online: 2 December 2020
Ethics approval and consent to participate
: The ethics approvals of this study were granted by the institutional review board (IRB) at Fox Chase Cancer Center (FCCC) as IRB protocols #99-802 and #11-866, and all patients and healthy donors provided informed consent in accordance with these protocols.
: Not applicable.
: This work was partially supported by funds from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (MSD), and JY, LA, and CM are employees of MSD. MC has advised Lilly, Cytodyn, Foundation Medicine, G1 Therapeutics, Amarex, and Sermonix and received honoraria from Pfizer and Foundation Medicine. KSC has received research funding from Janssen, Immune Oncology Biosciences, Genentech, BMS, Horizon Pharma, and NantKwest.
